Sino Biopharmaceutical Limited (SBHMY) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Wan Chai, 香港. 現CEOは S. Y. Tse.
SBHMY を有する IPO日 2017-09-05, 24,379 名の正社員, に上場 Other OTC, 時価総額 $14.2B.
Sino Biopharmaceutical Limited is an investment holding company and research and development pharmaceutical conglomerate headquartered in Hong Kong, operating primarily in the People's Republic of China. The company develops and commercializes a diverse portfolio of pharmaceutical products across multiple therapeutic areas, including oncology, cardio-cerebral vascular, hepatitis, orthopedic, and respiratory medicines, as well as advanced chemical formulations and generic pharmaceuticals. Beyond pharmaceutical manufacturing, the company operates an integrated healthcare ecosystem encompassing hospital operations, pharmaceutical distribution, optometry services, health food production, medical device development, and health information consultancy. Through its three main business segments—Modernised Chinese Medicines and Chemical Medicines, Investment, and Others—Sino Biopharmaceutical serves patients and healthcare providers across China with both traditional and contemporary therapeutic solutions. The company was incorporated in 2000 and maintains a comprehensive value chain from research and development through distribution and patient care services.